Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled 6-week trial of EVX-101 in adults with moderate to severe depression responding inadequately to current first-line antidepressant SSRI/SNRI therapy

Next Previous
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled 6-week trial of EVX-101 in adults with moderate to severe depression responding inadequately to current first-line antidepressant SSRI/SNRI therapy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbidopa/oxytriptan (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Therapeutic Use

Most Recent Events

  • 25 Oct 2024 According to Evecxia media release, as per Successful Completion of Pre-IND Meeting with the FDA Regarding Development of EVX-101 it provides provides clear path forward for filing an IND for conducting a Phase 2 trial in depression patients responding inadequately to standard of care and the focus of the pre-IND meeting was to receive FDA feedback and guidance on the phase 2 trial design for EVX-101.
  • 18 Sep 2023 According to Evecxia media release, Phase 2 study of adjunctive EVX-101 in depression patients with inadequate response to first-line antidepressants is expected to commence enrollment in Q1/2024.
  • 15 Mar 2023 According to Evecxia media release, company announced the planned design of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top